Cowen and Company reaffirmed their hold rating on shares of Genomic Health, Inc. (NASDAQ:GHDX) in a report issued on Friday. Cowen and Company currently has a $34.00 price objective on the medical research company’s stock.

Several other equities research analysts have also issued reports on the stock. BidaskClub upgraded shares of Genomic Health from a sell rating to a hold rating in a research note on Saturday, August 26th. Canaccord Genuity decreased their price target on shares of Genomic Health from $36.00 to $35.00 and set a buy rating for the company in a research note on Tuesday, August 15th. Piper Jaffray Companies restated a hold rating and set a $31.00 price target on shares of Genomic Health in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Genomic Health from a hold rating to a sell rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC restated a hold rating and set a $33.00 price target on shares of Genomic Health in a research note on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $32.00.

Genomic Health (NASDAQ:GHDX) opened at 31.78 on Friday. The company’s market cap is $1.10 billion. Genomic Health has a 12-month low of $26.37 and a 12-month high of $33.97. The company’s 50-day moving average price is $31.30 and its 200-day moving average price is $31.46.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $86.08 million. During the same quarter last year, the business posted ($0.18) EPS. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Equities analysts anticipate that Genomic Health will post ($0.01) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) Earns “Hold” Rating from Cowen and Company” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/04/genomic-health-inc-ghdx-earns-hold-rating-from-cowen-and-company.html.

In other Genomic Health news, insider Steven Shak sold 5,000 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $33.27, for a total value of $166,350.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of Genomic Health stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total transaction of $244,720.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 37,642 shares of company stock valued at $1,195,131. Insiders own 46.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Columbia Wanger Asset Management LLC lifted its holdings in shares of Genomic Health by 26.1% during the 1st quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock worth $50,625,000 after acquiring an additional 332,311 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Genomic Health by 27.1% during the 1st quarter. Renaissance Technologies LLC now owns 733,200 shares of the medical research company’s stock worth $23,088,000 after acquiring an additional 156,500 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Genomic Health by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock worth $49,256,000 after acquiring an additional 126,807 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Genomic Health by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock worth $9,259,000 after acquiring an additional 81,425 shares during the last quarter. Finally, Cowen Prime Services LLC lifted its holdings in shares of Genomic Health by 324.1% during the 2nd quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock worth $2,885,000 after acquiring an additional 67,735 shares during the last quarter. 88.91% of the stock is owned by institutional investors.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.